Thromb Haemost 1994; 71(05): 571-575
DOI: 10.1055/s-0038-1642484
Review Article
Schattauer GmbH Stuttgart

Anti-Glycoprotein Ib/IX and llb/llla Antibodies in Patients with Antiphospholipid Antibodies

Monica Galli
The Department of Haematology, Ospedali Riuniti, Bergamo, Italy
,
Maria Daldossi
The Department of Haematology, Ospedali Riuniti, Bergamo, Italy
,
Tiziano Barbui
The Department of Haematology, Ospedali Riuniti, Bergamo, Italy
› Author Affiliations
Further Information

Publication History

Received 18 November 1993

Accepted after revision 14 January 1994

Publication Date:
06 July 2018 (online)

Summary

Antiphospholipid antibodies, namely lupus anticoagulant (LA), anticardiolipin (aCL) type A and type B antibodies, are frequently associated with immune-mediated thrombocytopenia. Antiphospholipid antibodies have been suggested to bind to the phospholipids of the platelet membrane, thus participating to the process of platelet destruction, which leads to thrombocytopenia. However, a clear antiphospholipid (aPL) demonstration of such a role has never been given for antibodies. Conversely, autoantibodies directed against membrane-associated glycoproteins (GP) have been shown to be pathogenet- ically linked to the development of thrombocytopenia in patients with idiopathic thrombocytopenic purpura. For this reason, we have measured anti-GPIb/IX and GPlIb/IIIa IgG in the plasma of 68 patients with aPL antibodies by ELISA. The monoclonal antibody-specific immobilization of platelet antigen (MAIPA) assay was used.

Twenty-seven out of 68 patients with antiphospholipid antibodies (40%) had increased plasma levels of anti-GP antibodies. In particular, 7 of them had elevated anti-GPIIb/IIIa levels only, 6 had anti-GPIb/IX antibodies only, whereas in the remaining 14 cases both types of autoantibodies were found elevated. The level of anti-GP antibodies in plasma did not correlate with age, sex, clinical associated conditions, history of thrombosis, IgG aCL titer or the presence of a phospholipid- dependent inhibitor of coagulation. In contrast, a statistically significant association between thrombocytopenia and high anti-GP antibody titer was observed (p = 0.0458).

To establish whether there was cross-reactivity between antiphospholipid and anti-GP antibodies, adsorption experiments were performed using eardiolipin-containing liposomes or washed, normal, resting platelets. When patients’ plasma was mixed with resting washed platelets, only anti-GP antibodies were adsorbed on platelet membrane and subsequently eluted from platelets. Conversely, binding to cardio- lipin-containing liposomes but not to platelet surface was demonstrated for antiphospholipid antibodies.

In conclusion, our data indicate that high levels of anti-platelet glycoprotein antibodies are more frequently found in patients with antiphospholipid antibodies and thrombocytopenia and that they might be responsible, more than LA and/or aCL antibodies, for the development of thrombocytopenia.

 
  • References

  • 1 Harris EN, Balestrieri G, Tincani A, Gharavi AE. The immunology of phospholipid-binding antibodies in the antiphospholipid syndrome and related disorders. In: Phospholipid-binding antibodies Harris EN, Exner T, Hughes GRV, Asherson RA. (eds) CRC Press; Inc: 1991: 123-37
  • 2 Bevers EM, Galli M, Barbui T. et al. Lupus anticoagulant IgG’s (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66: 629-632
  • 3 McNeil HP, Simpson RJ, Chesterman C, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (Apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4124
  • 4 Galli M, Comfurius P, Maassen C. et al Anticardiolipid antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-1547
  • 5 Galli M, Comfurius P, Barbui T. et al. Anticoagulant activity of β2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost 1992; 68: 297-300
  • 6 Italian Registry of Antiphospholipid Antibodies (IR-APA). Thrombosis and thrombocytopenia in antiphospholipid syndrome (idiopathic and secondary to SLE): first report from the Italian Registry. Haematologica (in press).
  • 7 Shapiro SS, Thiagarajan P. Lupus anticoagulants. Progr Hemostas Thromb 1982; 6: 263-286
  • 8 Orlando E, Cortelazzo S, Marchetti M. et al. Prolonged bleeding time in patients with lupus anticoagulant. Thromb Haemost 1992; 68: 495-499
  • 9 Fleck RA, Rapaport SI, Rao SI. Anti-prothrombin antibodies and the lupus anticoagulant. Blood 1988; 72: 512-519
  • 10 Hedge UM. Platelet antibodies in immune thrombocytopenia. Blood Reviews 1992; 6: 34-42
  • 11 Editorial. Lupus anticoagulant. Lancet 1984; ii: 1157-1158
  • 12 Hams EN, Gharavi AE, Hedge U. et al. Anticardiolipin antibodies in autoimmune thrombocytopenic purpura. Br J Haematol 1985; 59: 231-234
  • 13 Galli M, Bevers EM, Comfurius P. et al. Effect of antiphospholipid antibodies on procoagulant activity of activated platelets and platelet-derived microvesicles. Br J Haematol 1993; 83: 466-472
  • 14 Shi W, Chong BH, Chesterman CN. β2-glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: differences with lupus anticoagulants. Blood 1993; 81: 1255-1262
  • 15 Tan EM, Cohen AS, Fries JF. et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1276
  • 16 Loizou S, McCrea JD, Rudge AC. et al. Measurement of anticardiolipin antibodies by enzyme-linked immunosorbent assay: standardization and quantitation of results. Clin Exp Immunol 1985; 62: 738-744
  • 17 Exner T, Triplett D. Lupus anticoagulants: characteristics, methods of laboratory detection and some clinical associations. In: Phospholipid-binding antibodies Harris EN, Exner T, Hughes GRV, Asherson RA. (eds). CRC Press; Inc: 1991: 141-158
  • 18 Exner T, Rickard KA, Kronenberg A. Asensitive test demonstrating lupus anticoagulant and its behavioural patterns. Br J Haematol 1978; 40: 143-151
  • 19 Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulant. Blood 1986; 68: 869-874
  • 20 Kiefel V, Santoso S, Kaufmann E, Mueller-Eckhardt C. Autoantibodies against glycoprotein Ib/IX: a frequent finding in autoimmune thrombocytopenic purpura. Br J Haematol 1991; 79: 256-262
  • 21 Kiefel V, Santoso S, Weisheit M, Mueller-Eckhardt C. Monoclonal antibody-specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood 1987; 70: 1722-1726
  • 22 Leeksa OC, Giltaj IC, Zandbergen-Spaargaren J. et al. The platelet alloantigen ZWa or PLA1 is expressed by cultured endothelial cells Br J Haematol 1987; 66: 369-373
  • 23 McMillan R, Tani P, Millard F. et al. Platelet associated and plasma antiglycoprotein antibodies in chronic ITP Blood 1987; 70: 1040-1045
  • 24 Furihata K, Nugent DJ, Bissonette A. et al. On the association of platelet specific alloantigen Pen2 with glycoprotein IIIa, Evidence for heterogeneity of glycoprotein IIIa. J Clin Invest 1987; 80: 1624-1630
  • 25 Beardsley DS, Ho JJ, Beyer EC. Varicella associated thrombocytopenia: antibodies against an 85 kD thrombin sensitive protein (GPV?). Blood 1985; 66: 1030a
  • 26 Beer JH, Rabaglio M, Berchtold P. et al. Autoantibodies against the platelet glycoproteins (GP) Ilb/IIIa, Ia/IIa and IV and partial deficiency in GPIV in a patient with bleeding disorder and a defective platelet collagennteraction. Blood 1993; 82: 820-829
  • 27 Warkentin TE, Smith JW, Hayward CPM. et al. Thrombocytopenia caused by passive transfusion of anti-glycoprotein Ia/IIa alloantibody (anti-HPA- 5b). Blood 1992; 79: 2480-2484
  • 28 Berchtold P, Wenger M. Autoantibodies against platelet glycoproteins in autoimmune thrombocytopenic purpura: their clinical significance and response to treatment. Blood 1993; 81: 1246-1250
  • 29 Khamashta MA, Harris NE, Gharavi AE. et al. Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membrane. Ann Rheum Dis 1988; 47: 849-854
  • 30 Hasselaar P, Derksen RHWM, Blokzijl L, de Groot P. Cross-reactivity of antibodies directed against cardiolipin, DNA, endothelial cells and blood platelets. Thromb Haemost 1988; 63: 169-173
  • 31 Rauch J, Meng QH, Tannenbaum H. Lupus anticoagulant and antiplatelet properties of human hybridoma autoantibodies. J Immunol 1987; 139: 2598-2604
  • 32 Schroit AJ, Zwaal RFA. Transbilayer movement of phospholipids in red cell and platelet membranes. Biochim Biophys Acta 1991; 1071: 313-329
  • 33 Wicher K, Wicher V. Phospholipid antibodies in natural and experimental syphilis. In: Phospholipid-binding antibodies Harris EN, Exner T, Hughes GRV, Asherson RA. (eds). CRC Press; Inc: 1991: 97-105
  • 34 Abrams C, Shattil SJ. Immunological detection of activated platelets in clinical disorders. Thromb Haemost 1991; 65: 467-473
  • 35 Jy W, Horstman LL, Arce M, Ahn YS. Clinical significance of platelet microparticles in autoimmune thrombocytopenias. J Lab Clin Med 1992; 119: 334-345
  • 36 Galli M, Cortelazzo S, Viero P. et al. Interaction between platelets and lupus anticoagulant. Eur J Haematol 1988; 41: 88-94
  • 37 Out HJ, de Groot PG, van Vliet M. et al. Antibodies to platelets in patients with antiphospholipid antibodies. Blood 1991; 77: 2655-9
  • 38 Biasiolo A, Pengo V. Antiphospholipid antibodies are not present in the membrane of gel-filtered platelets of patients with IgG anticardiolipin antibodies lupus anticoagulant and thrombosis. Blood Coagul Fibrinol 1993; 4: 425-8